leadf
logo-loader
viewSourceBio International PLC

Proactive Analyst Emma Ulker talks about lab services and products provider Source Bio

SourceBio International (LON:SBS) has made a huge impact on its return to public markets. It reported a 139% rise in fiscal 2020 (FY20) reported revenues to £50.7mln from £21.2mln and underlying earnings (EBITDA) of £14mln, vs £3mln in FY19. Proactive Analyst Emma Ulker explains why this growth has been driven largely on its rapid mobilisation of resources to create a new fourth division; infectious disease testing services.

Click here to read Emma Ulker's initiation report on SourceBio

Quick facts: SourceBio International PLC

Price: 188.055 GBX

AIM:SBI
Market: AIM
Market Cap: £139.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SourceBio International PLC named herein, including the promotion by the Company of SourceBio International PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: UK borrowing soars in January and British retail sales...

FTSE 100 slipped lower on confirmation UK government borrowing hit a record high of £8.8bn in January. London’s leading index slipped 11 points to 6,605 in early trading. The Office for National Statistics reported UK retail sales also dropped 8.2% in January compared to December because of...

1 week, 6 days ago

2 min read